>

Ian Davis - Johnson Johnson Independent Director

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:3em;padding-top: 40px;;'>JNJ</div>
JNJ -- USA Stock  

Fiscal Quarter End: March 31, 2020  

  Director
Mr. Ian E.L. Davis is an Independent Director of the Company. Mr. Davis is currently nonexecutive Chairman, RollsRoyce Holdings plc. Mr. Davis retired from McKinsey Company in 2010 as a Senior Partner, having served as Chairman and Worldwide Managing Director from 2003 until 2009. In his more than 30 years at McKinsey, he served as a consultant to a range of global organizations across the public, private and notforprofit sectors. Prior to becoming Chairman and Worldwide Managing Director, he was Managing Partner of McKinseys practice in the United Kingdom and Ireland. His experience included oversight for McKinsey clients and services in Asia, Europe, the Middle East and Africa, as well as expertise in the consumer products and retail industries
Age: 67  Director Since 2010      
732 214-0332  www.jnj.com
Davis is a Director of Teach for All, Inc., a global network of independent social enterprises working to expand educational opportunities in their nations; BP plc., a global energy group; and Majid Al Futtaim Holding LLC; and a Senior Advisor at Apax Partners, a private equity firm.

Management Efficiency

The company has 30.43 B in debt with debt to equity (D/E) ratio of 50.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Johnson Johnson has Current Ratio of 1.3 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Peter WendellMerck Company
2003
Paul RothmanMerck Company
2015
Elizabeth DohertyNovartis AG
2016
Karen WalkerEli Lilly And Company
2018
Michael GreenbergAllergan Plc
2018
Christopher BodineAllergan Plc
2013
Jackson TaiEli Lilly And Company
2013
Suzanne JohnsonPfizer
2007
James BloemAllergan Plc
2013
Ron TaylorAllergan Plc
2013
Jacqueline BartonGilead Sciences
2018
Dan LittmanPfizer
2018
Frances FergussonPfizer
2009
Kelly KramerGilead Sciences
2016
Baroness VaderaAstrazeneca PLC
2011
Leslie BrunMerck Company
2016
Ronald BlaylockPfizer
2017
Michael GrobsteinBristol Myers Squibb Company
2007
James KiltsPfizer
2007
Gayle WilsonGilead Sciences
2001
Pierre LandoltNovartis AG
1996

Company Summary

Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange.Johnson Johnson (JNJ) is traded on BATS Exchange in USA. It is located in One Johnson and Johnson Plaza, New Brunswick, NJ 08933, United States and employs 135,100 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

A Washington, Independent DirectorView
Jennifer Doudna, Independent DirectorView
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. CommitteeView
William Perez, Independent DirectorView
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication OfficerView
Marillyn Hewson, Independent DirectorView
Jorge Mesquita, Executive Vice President Worldwide Chairman - ConsumerView
Mary Coleman, Independent DirectorView
Michael Ullmann, VP, General Counsel and Member of Executive CommitteeView
Joaquin Duato, Executive Vice President Worldwide Chairman - PharmaceuticalsView
Kathy Wengel, Executive Vice President Chief Global Supply Chain OfficerView
Jennifer Taubert, Executive Vice President - Worldwide Chairman, PharmaceuticalsView
Mary Beckerle, Independent DirectorView
Sandra Peterson, Group Worldwide Chairman and Member of Executive CommitteeView
Scott Davis, DirectorView
Louise Mehrotra, Vice President Investor RelationsView
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical DevicesView
Ronald Williams, Independent DirectorView
Kathryn Wengel, Executive Vice President Chief Global Supply Chain OfficerView
D Davis, Independent DirectorView
Hubert Joly, DirectorView
Anne Mulcahy, Lead Independent DirectorView
Joseph Wolk, Chief Financial Officer, Executive Vice PresidentView
Thibaut Mongon, Executive Vice President Worldwide Chairman, ConsumerView
Ian Davis, Independent DirectorView
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive CommitteeView
Mark McClellan, Independent DirectorView
Charles Prince, Independent DirectorView
Eugene Washington, Independent DirectorView
Dominic Caruso, CFO, VP of Fin. and Member of Executive CommitteeView
Peter Fasolo, Chief Human Resource Officer, Executive Vice PresidentView
Susan Lindquist, Independent DirectorView
Mark Weinberger, DirectorView

Stock Performance Indicators

Did you try this?

Run Equity Forecasting Now

   

Equity Forecasting

Use basic forecasting models to generate price predictions and determine price momentum
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Please also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.